...
首页> 外文期刊>Cancer Imaging >Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis
【24h】

Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis

机译:常规表观扩散系数的扩散加权成像在横冲化疗栓塞后诊断残留或复发性肝细胞癌的实用性:META分析

获取原文

摘要

Background Accurate and early diagnosis of residual tumors or intrahepatic recurrences after TACE is critically needed for determining the success of treatments and for guiding subsequent therapeutic planning. This meta-analysis was performed to assess the efficacy of diffusion weighted imaging (DWI) with the quantitative apparent diffusion coefficient (ADC) value in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization (TACE). Materials and methods A comprehensive literature search of PubMed, Embase, Web of Science, Scopus and the Cochrane Library database, from inception to July 2019, was conducted to select original studies on diagnosing residual or recurrent HCCs after TACE using DWI sequence with its ADC value. Two researchers independently chose study, extracted data, conducted meta-analysis, and evaluated methodological quality according to Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Results Twelve studies comprising 624 patients and 712 tumors were finally included. The pooled sensitivity, specificity and AUC value of DWI in diagnosing residual or recurrent HCCs after TACE were 85% (95%CI: 74–92%), 83% (95%CI: 75–88%) and 0.90 (95%CI: 0.87–0.92), respectively. Residual or recurrent HCCs have significantly lower ADC value than necrotic tumors (MD?=?-0.48, 95%CI: ??0.69~???0.27, P ?0.01). Conclusion This study demonstrated that DWI performed better in diagnosing residual or recurrent HCCs after TACE, and ADC value may serve as alternatives for further evaluation of residual or recurrent leisions in HCC patients after TACE.
机译:背景技术TACE后的残留肿瘤或肝内复发的准确性和早期诊断,用于确定治疗的成功和引导后续治疗规划。进行该META分析以评估扩散加权成像(DWI)在横发化疗栓塞(TACE)后诊断残留或复发性肝细胞癌的定量表观扩散系数(ADC)值。材料和方法在2019年至2019年7月开始,从成立到2019年7月的PubMed,Embase,Scopus和Cochrane库数据库的全面文献搜索,以选择在使用DWI序列与其ADC值的TACE后诊断残留或复发性HCC的原创研究。两位研究人员独立选择研究,提取数据,进行元分析,并根据诊断准确性研究-2(Quadas-2)工具的质量评估评估的方法质量。结果,最终包括12例患者和712例肿瘤的12项研究。 DWI在TACE后诊断残留或复发性HCCs的汇集性,特异性和AUC值为85%(95%CI:74-92%),83%(95%CI:75-88%)和0.90(95%CI) :0.87-0.92)分别。残留或复发性HCC比坏死肿瘤的ADC值显着降低(MD?=α - 0.48,95%CI:0.69〜??? 0.27,P <0.01)。结论本研究表明,DWI在TACE后诊断残留或复发性HCC诊断,ADC值可以作为在TACE后进一步评估HCC患者中残留或复发空间的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号